Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Jun 6;92(11):2049-58.
doi: 10.1038/sj.bjc.6602617.

An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk

S A Lee  1 , R K Ross, M C Pike
Affiliations
Meta-Analysis

An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk

S A Lee et al. Br J Cancer. .

Abstract

Results from the Women's Health Initiative (WHI) trial support findings from observational studies that oestrogen-progestin therapy (EPT) use is associated with an increase in breast cancer risk. We conducted a meta-analysis using EPT-specific results from the Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC) pooled analysis and studies published since that report to obtain an overview of EPT use and breast cancer risk. We also assessed risk by histologic subtype of breast cancer, by schedule of the progestin component of EPT, and by recency of use. We estimate that overall, EPT results in a 7.6% increase in breast cancer risk per year of use. The risk was statistically significantly lower in US studies than in European studies - 5.2 vs 7.9%. There was a significantly higher risk for continuous-combined than for sequential EPT use in Scandinavian studies where much higher total doses of progestin were used in continuous-combined than in sequential EPT. We observed no overall difference in risk for lobular vs ductal carcinoma but did observe a slightly higher risk for current vs past EPT use.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Studies included in overall analysis of EPT and risk of breast cancer: odds ratios with 95% CIs per year of use.
See this image and copyright information in PMC

References

    1. Back DJ, Bates M, Breckenridge AM, Hall JM, MacIver M, Orme ML, Park BK, Rowe PH (1981) The pharmacokinetics of levonorgestrel and ethynylestradiol in women – studies with Ovran and Ovranette. Contraception 23: 229–239 - PubMed
    1. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101 - PubMed
    1. Chen CL, Weiss NS, Newcomb P, Barlow W, White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287: 734–741 - PubMed
    1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289: 3243–3253 - PubMed
    1. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350: 1047–1059 - PubMed

Publication types